A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment
What is the purpose of this trial?
The purpose of this study is to evaluate response rate, survival, safety and tolerability of YM155 given in combination with rituximab in subjects with Non-Hodgkin's Lymphoma.
- 18 Years and older
- Astellas Pharma Inc
- November 2009
- Last Updated:
- April 11, 2013
- Study HIC#:
Clinicaltrials.gov ID: NCT01007292